Buy or Sell Medtronic Stock Now?

Medtronic (MDT) is scheduled to report earnings on August 19, 2025, with consensus estimates projecting flat EPS at $1.23 on sales of $8.37 billion. Historically, MDT's post-earnings stock performance has been highly unpredictable, exhibiting a 50/50 split for positive (median +2.5%) or negative (median -3.8%) next-day returns over the past five years. This volatility, combined with the stock's significant long-term underperformance relative to the S&P 500, suggests challenges for both event-driven trading and buy-and-hold strategies.

Analysis

Medtronic (MDT) faces a critical earnings report on August 19, 2025, with consensus forecasting flat year-over-year EPS of $1.23 despite a projected increase in sales to $8.37 billion from $7.92 billion, potentially signaling margin pressure. The stock's historical reaction to earnings is highly unpredictable, presenting a significant challenge for event-driven strategies. Over the past five years (20 observations), the one-day post-earnings move has been positive exactly 50% of the time, with a median gain of 2.5%, and negative the other 50%, with a more severe median loss of -3.8%. This negative skew is further compounded by a more recent trend over the last three years where the probability of a positive return has declined to 42%. This short-term volatility exists within a context of severe long-term underperformance; MDT has lagged the S&P 500 for five consecutive years and has seen its share price decline from approximately $100 to $95 since early 2021, a period during which the index climbed roughly 70%. While the company maintains a substantial fundamental base with a $119 billion market capitalization and $6.5 billion in last-twelve-months operating profit, this has not translated into shareholder returns, reinforcing the article's assessment that it is not an ideal buy-and-hold candidate.

Key Decisions for Investors

• Given the 50/50 split in historical post-earnings reactions and a negative risk-reward skew where median losses (-3.8%) exceed median gains (+2.5%), investors should avoid making simple directional bets ahead of the earnings release.
• Long-term investors should critically reassess positions in Medtronic due to its profound and multi-year underperformance against the S&P 500, which suggests a persistent drag on portfolio returns.
• Focus on management's forward guidance and commentary on profit margins in the upcoming report, as the flat YoY EPS forecast on higher revenue is a potential red flag for profitability.
• Consider a reactive trading strategy by waiting for the initial market reaction post-earnings and then assessing short-to-medium term return correlations, rather than taking on the uncertainty of a pre-earnings position.